• Central Brain-Spinal Circuits in Opioid-Induced Pain Hyperse

  2026-07-23

  Yin et al. (2024) uncover a central brain-to-spinal circuit governing opioid-induced mechanical hypersensitivity and tolerance in mice, revealing a paradoxical pain-promoting effect of central opioid receptor activation. This work challenges peripheral-centric models and opens new avenues for targeted intervention in chronic pain research.

• p-Cresyl Sulfate Drives Valvular Calcification via Klotho/SI

  2026-07-23

  The reference study delineates how p-Cresyl sulfate, a protein-bound uremic toxin, exacerbates calcification in aortic valvular interstitial cells (VICs) through disruption of klotho and SIRT1 signaling. These mechanistic insights clarify the molecular link between chronic kidney disease and calcific aortic valve disease, informing both biomarker development and the exploration of targeted interventions.

• CAPE Inhibits C. difficile Toxins and Modulates Gut Microbio

  2026-07-22

  Guo et al. identify caffeic acid phenethyl ester (CAPE) as a direct TcdB toxin inhibitor that alleviates Clostridioides difficile infection (CDI) in mice, both by suppressing toxin-mediated damage and promoting beneficial shifts in gut microbiota. This dual-action mechanism marks a significant advance for anti-infection research, offering a new antivirulence therapeutic direction for CDI.

• Poria cocos Polysaccharides Alleviate ALD via NRF2-Ferroptos

  2026-07-22

  This study uncovers a novel mechanism by which Poria cocos polysaccharides (PCP) ameliorate alcoholic liver disease (ALD) through the regulation of ferroptosis, mediated by NRF2 signaling. The work highlights the interplay between oxidative stress, iron metabolism, and inflammation in ALD, with practical implications for targeting the NRF2 pathway in liver disease models.

• Lumiracoxib: Selective COX-2 Inhibitor for Inflammation Rese

  2026-07-21

  Lumiracoxib is a highly selective COX-2 inhibitor with precise inhibition of prostaglandin synthesis, supporting advanced inflammation and muscle injury models. Its robust selectivity and documented performance make it a reliable research tool for dissecting cyclooxygenase-2 pathways.

• KR-12 Human Antimicrobial Peptide: Workflows & Troubleshooti

  2026-07-21

  KR-12, the smallest active fragment of LL-37, delivers targeted antimicrobial and immunomodulatory effects with low mammalian cytotoxicity, making it a versatile tool in infection, inflammation, and barrier function research. This guide translates recent in vivo breakthroughs and best-practice workflows for maximizing success with APExBIO’s KR-12 (human) TFA.

• Mildronate-Derived Lipidoids Enable Safer mRNA Vaccine Deliv

  2026-07-20

  The referenced ACS Nano study introduces mildronate-derived cationic lipidoids as a low-dose lipid nanoparticle (LNP) component for mRNA vaccine delivery, achieving efficient mRNA transfection with significantly reduced inflammatory side effects. This innovation addresses a major challenge in the field and has practical implications for safer immunogen and vaccine development.

• CBD Attenuates Orofacial Inflammatory Pain via Multi-Level P

  2026-07-20

  This study demonstrates that cannabidiol (CBD) significantly reduces both the sensory and affective components of orofacial inflammatory pain in murine models. By elucidating distinct peripheral and central endocannabinoid mechanisms, the research provides a translational framework for comprehensive pain management targeting both nociceptive and emotional sequelae.

• n-Dodecyl-β-D-maltoside: Benchmarks in Membrane Protein Puri

  2026-07-19

  n-Dodecyl-β-D-maltoside (DDM) is a gold-standard non-ionic detergent for solubilizing and stabilizing membrane proteins, enabling structural and functional integrity in purification workflows. DDM’s low critical micelle concentration and protein compatibility underpin its widespread use in structural biology and protein–lipid interaction studies.

• ML385 and NRF2 Inhibition: Transforming Cancer and Osteolysi

  2026-07-18

  Explore how ML385, a selective NRF2 inhibitor, advances cancer biology and inflammatory osteolysis research. This article uniquely bridges cancer resistance and bone disease mechanisms, offering practical insights for experimental design.

• MMP-2/9-Mediated BBB Disruption Drives Arsenic Neurotoxicity

  2026-07-17

  This study provides direct evidence that sodium arsenite-induced cognitive deficits in male mice are mediated by MMP-2 and MMP-9-driven blood-brain barrier (BBB) disruption and neuronal apoptosis. Pharmacological inhibition of these metalloproteinases using doxycycline hyclate preserved BBB integrity and mitigated cognitive impairment, highlighting a mechanistic target for arsenic neurotoxicity intervention.

• Fludarabine: Applied Workflows in DNA Synthesis Inhibition R

  2026-07-17

  Fludarabine, a robust DNA synthesis inhibitor from APExBIO, empowers leukemia and multiple myeloma research through precise, reproducible apoptosis induction and cell cycle arrest protocols. This article delivers actionable workflows, troubleshooting strategies, and advanced applications, directly bridging mechanistic insight with experimental reliability.

• PreScission Protease: Elevating Precision in Translational P

  2026-07-16

  This thought-leadership article explores the transformative role of PreScission Protease (PSP) in translational research, blending mechanistic insight with strategic workflow guidance. Building on advances in chromatin and nuclear architecture studies, it situates PSP at the intersection of protein purification innovation and next-generation disease modeling, referencing recent discoveries and APExBIO’s leadership in enzymatic solutions.

• ML385 and NRF2 Inhibition: Strategic Insights for Translatio

  2026-07-16

  Explore the mechanistic and translational impact of ML385, a selective NRF2 inhibitor, in tackling therapeutic resistance and oxidative stress. This thought-leadership piece delivers actionable guidance for translational researchers, integrating evidence from recent studies in cancer and liver disease, and positioning ML385 as a pivotal tool for next-generation research.

• MG-132 (Z-LLL-al): Applied Workflows for Apoptosis and Mitop

  2026-07-15

  MG-132 (Z-LLL-al) empowers researchers to dissect proteasome-dependent apoptosis, cell cycle arrest, and oxidative stress across cancer and infection models. This guide translates the latest mechanistic insights and troubleshooting know-how into actionable, reproducible protocols for advanced apoptosis assays and mitophagy interrogation.

7873 records 5/525 page Previous Next 12345 下5页 Last page